THURSDAY, Dec. 8 (HealthDay News) -- U.S. health advisers recommended Thursday that several newer forms of oral contraceptives lift revised labels warning about an augmenting risk of potentially deadly blood clots.
The U.S. Food and Drug Administration advisers voted 21-5 in preference of the new labels for verbal contraceptives such as Bayer's Yaz or Yasmin. Both contain a newer form of synthetic progestin hormone called drospirenone, which could boost a chances of dangerous clots in a legs or lungs, compared to comparison forms of verbal contraceptives. The newer contraceptives have been successfully marketed on a grounds that they have fewer of a unwanted side effects of comparison hormone pills such as bloating, mood swings and acne.
"Clearly, a diction is unsound and incomplete," pronounced Dr. Richard Bockman, of New York's Hospital for Special Surgery, a Associated Press reported. "Adverse events have to be done striking so physicians and patients are wakeful of a consequences."
Earlier Thursday, a row members voted 15 to 11 that a newer contraceptives, that gained initial FDA capitulation in 2001, are a viable method of birth control, and that a advantages of preventing pregnancy outweigh a health risks.
While a FDA isn't thankful to follow a recommendations of a advisory panels, it customarily does so.
Several doctors pronounced in allege of a conference that a intensity increased risk of clots is not great, yet should not be dismissed, either.
"It's a low risk yet a risk exists," pronounced Dr. Tara Narula, a cardiologist during Lenox Hill Hospital in New York City. "The thought of a FDA looking during this and potentially augmenting a warning has no downside. If anything, it increases recognition and that can usually be a good thing."
Women who fume or have a story of blood clots should not be holding oral contraceptives, she said.
Narula combined that women deliberation an oral contraceptive competence wish one of a comparison ones. "If we are going to take a risk during slightest have it be as low as possible. And if that means holding one of a comparison generation drugs, that might be improved for we than holding some of a newer ones even yet they're rarely marketed and promoted," she said.
Dr. Christopher Estes, an partner highbrow of obstetrics and gynecology during a University of Miami School of Medicine, pronounced "the information that exists per a risks of these pills needs to be taken with a grain of salt. We have famous perpetually that contraceptive pills that enclose estrogen and progesterone all rouse a risk of blood clots, heart attack and stroke. The volume that it [newer contraceptives] raises a risk is small, and over an whole race a boost in risk is not very great."
Some women, generally those during risk for blood clots, heart conflict or stroke, should substantially not use any verbal contraceptive, Estes said, observant that pregnancy itself increases a chances of carrying a blood clot in a leg or lung most some-more than any birth control pill.
An FDA-funded examination that stirred this week's advisory row assembly was initial expelled in October, and concerned a medical histories of some-more than 800,000 American women, all of whom were on some form of birth control between 2001 and 2008. The investigate found that women holding a newer oral contraceptives gifted a aloft rate of clots than women on comparison forms of "the pill."
The examination also found that women on dual other forms of birth control -- the Ortho Evra patch and a NuvaRing vaginal ring from Merck -- had a higher rate of clots.
The Oct proclamation came a day after a recover of a investigate in BMJ that also found newer birth control pills were tied to a aloft risk for clots.
In that study, researchers reviewed information on all Danish women, aged 15 to 49, who were not profound between Jan 2001 and Dec 2009. During that time, some-more than 4,200 initial episodes of clots occurred.
Women holding birth control pills with a newer progestin hormone had twice a risk of clots compared to those who took a comparison form of contraceptive pills, a investigate found.
Compared to women who did not use birth control pills, a clot risk was 3 times aloft among those who used pills with levonorgestrel, and six times aloft among those who took pills with drospirenone, desogestrel or gestodene.
But a comprehensive risk of blood clots compared with a newer pills remained comparatively low, about 10 per 10,000 women, according to a University of Copenhagen researchers.
More information
The American College of Obstetricians and Gynecologists has some-more about .
News referensi http://news.yahoo.com/fda-advisers-newer-forms-pill-revised-warning-labels-044806294.html
No comments:
Post a Comment